Agios Pharmaceuticals (AGIO)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.57 (+0.97%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Key Insights

Critical company metrics and information
  • Share Price

    $59.45
  • Market Cap

    $3.39 Billion
  • Total Outstanding Shares

    57.03 Million Shares
  • Total Employees

    386
  • Dividend

    No dividend
  • IPO Date

    July 24, 2013
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.agios.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-329.16 Million
Net Cash Flow From Operating Activities, Continuing$-329.16 Million
Net Cash Flow$189.40 Million
Net Cash Flow From Financing Activities$10.45 Million
Net Cash Flow From Investing Activities, Continuing$508.11 Million
Net Cash Flow, Continuing$189.40 Million
Net Cash Flow From Financing Activities, Continuing$10.45 Million
Net Cash Flow From Investing Activities$508.11 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Cost Of Revenue$3.49 Million
Operating Expenses$436.36 Million
Selling, General, and Administrative Expenses$140.39 Million
Net Income/Loss Attributable To Parent$674.31 Million
Benefits Costs and Expenses$-694.56 Million
Net Income/Loss Available To Common Stockholders, Basic$674.31 Million
Research and Development$295.96 Million
Costs And Expenses$439.85 Million
Gross Profit$29.38 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Income/Loss$-406.98 Million
Revenues$32.87 Million
Basic Average Shares$113.62 Million
Income/Loss From Continuing Operations After Tax$674.31 Million
Net Income/Loss$674.31 Million
Basic Earnings Per Share$11.86
Income/Loss From Continuing Operations Before Tax$727.43 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Earnings Per Share$11.66
Diluted Average Shares$115.12 Million
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$45.67 Million
Fixed Assets$11.82 Million
Cash$1.70 Billion
Current Liabilities$119.45 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$1.63 Billion
Current Assets$1.07 Billion
Other Current Liabilities$84.62 Million
Wages$17.69 Million
Liabilities And Equity$1.79 Billion
Equity$1.63 Billion
Accounts Payable$17.14 Million
Other Non-current Assets$705.79 Million
Inventory$26.43 Million
Assets$1.79 Billion
Liabilities$165.12 Million
Noncurrent Assets$717.61 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.